Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    A banner announces an NIH website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content during the transition.
    Difference
    1%
    Check dated 2026-10-25T13:49:13.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:15:07.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.0 to v3.7.1 while the study page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:57:08.000Z thumbnail image
  4. Check
    21 days ago
    No Change Detected
  5. Check
    28 days ago
    Change Detected
    Summary
    The page previously displayed a 403 Forbidden error, and now presents the full study record for NCT04695470, including sections on study overview, eligibility criteria, design details, interventions (Fruquintinib with Sintilimab), primary outcomes, enrollment, and locations.
    Difference
    43%
    Check dated 2026-09-27T20:31:43.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study content, replacing the study details with a standard error page and site header/footer.
    Difference
    17%
    Check dated 2026-09-20T22:29:59.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Post-update, the page shows Revision: v3.6.6, replacing v3.6.5. This indicates a small behind-the-scenes update to the page software without changing displayed study details.
    Difference
    0.1%
    Check dated 2026-08-30T21:59:13.000Z thumbnail image

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.